Related Experiment Video
Updated: Dec 20, 2025
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
11.8K
DCLK-1 LEVEL IN MULTIPLE SCLEROSIS PATIENTS AND ITS CORRELATION WITH CLINIC
Fatma ŞİmŞek1, Nurinnisa ÖztÜrk2
1Atatürk University, Faculty of Medicine, Department of Neurology, Erzurum, Turkey.
Multiple Sclerosis and Related Disorders
|May 30, 2020
Summary
Doublecortin-like kinase 1 (DCLK1) levels are lower in multiple sclerosis patients, indicating disrupted axonal transport. This finding suggests DCLK1 may be a therapeutic target for neurodegeneration in multiple sclerosis.
Area of Science:
- Neuroscience
- Biochemistry
Background:
- Multiple sclerosis (MS) is a neurodegenerative disease characterized by disrupted axonal transport.
- Doublecortin-like kinase 1 (DCLK1) is implicated in axonal transport processes.
Purpose of the Study:
- To determine Doublecortin-like kinase 1 (DCLK1) levels in multiple sclerosis (MS) patients.
- To investigate the correlation between DCLK1 levels and MS disease parameters.
Main Methods:
- The study involved 30 MS patients and 30 healthy controls.
- DCLK1 levels were measured in venous blood samples using the ELISA method.
- Clinical data including disease duration, attack frequency, and EDSS scores were recorded.
Main Results:
- DCLK1 levels were significantly lower in MS patients compared to healthy controls.
- No significant correlation was found between DCLK1 levels and disease duration, attack frequency, or EDSS scores.
Conclusions:
- Reduced DCLK1 levels in MS patients support the hypothesis of disrupted axonal transport.
- Enhancing DCLK1 expression could be a potential therapeutic strategy to mitigate neurodegeneration and improve clinical outcomes in MS.
